Colorectal adenocarcinoma (CRC), the second leading cancer‐related death in the United
States, remains a global public health issue. Sporadic CRC is considered the result of …

Breast cancer is a heterogeneous disease. Thanks to extensive efforts from research
scientists and clinicians, treatment for breast cancer has advanced into the era of targeted …

Targeting tumors using miniature antibodies is a novel and attractive therapeutic approach,
as these biomolecules exhibit low immunogenicity, rapid clearance, and high targeting …

Background In view of the prominent role in cancer cell biology and alteration in substantial
numbers of ESCC, defining EGFR molecular characteristics relevant to patient prognosis is …

Thienopyrimidines are fused heterocyclic ring systems; structurally resemble purines,
exerting pharmacological potential in different aspects. They are known to play a crucial role …

Aberrant expression or function of epidermal growth factor receptor (EGFR) or the closely
related human epidermal growth factor receptor 2 (HER2) can promote cell proliferation and …

Lysosomal cysteine peptidases–cysteine cathepsins–are general intracellular protein-
degrading enzymes that control also a variety of specific physiological processes. They can …

Progression or recurrence due to resistance to aromatase inhibitors (AIs) is a significant
clinical problem for a considerable number of patients with breast cancer. Programmed cell …

Breast cancer is the most common type of cancer for women worldwide with a lifetime risk
amounting to a staggering total of 10%. It is well established that the endogenous synthesis …

Rapidly accelerated fibrosarcoma (RAF) inhibitors are first-line treatments for patients
harboring V600E/K mutant BRAF melanoma. Although RAF inhibitors produce high …